As filed with the Securities and Exchange Commission on May 11, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
HORIZON PHARMA PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
| Ireland | Not Applicable | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| Connaught House, 1st Floor 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland 011-353-1-772-2100 |
Not Applicable | |
| (Address and Telephone Number of Principal Executive Offices) | (Zip Code) |
Horizon Pharma Public Limited Company 2014 Equity Incentive Plan
(Full title of the plan)
Timothy P. Walbert
Chairman, President and Chief Executive Officer
Horizon Pharma plc
c/o Horizon Pharma, Inc.
150 South Saunders Road
Lake Forest, Illinois 60045
(224) 383-3000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Lynda Kay Chandler, Esq.
Sean M. Clayton, Esq.
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
(858) 550-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large Accelerated filer | ☒ | Accelerated filer | ☐ | |||||
| Non-accelerated filer | ☐ | (Do not check if a smaller reporting company) | Smaller reporting company | ☐ | ||||
| Emerging growth company | ☐ | |||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
Title of securities to be registered |
Amount to be registered (1)(2) |
Proposed maximum offering price per share (3) |
Proposed maximum aggregate offering price (3) |
Amount of registration fee (4) | ||||
| Horizon Pharma Public Limited Company 2014 Equity Incentive Plan Ordinary Shares, nominal value $0.0001 per share |
10,800,000 shares | $13.96 | $150,768,000.00 | $18,770.62 | ||||
| (1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall also cover any additional ordinary shares of the Registrant (the “Ordinary Shares”) that become issuable under the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan, as amended (the “2014 Plan”), by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding Ordinary Shares. |
| (2) | Consists of 10,800,000 additional Ordinary Shares available for issuance under the 2014 Plan. Ordinary Shares issuable under the 2014 Plan were previously registered on Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission on September 22, 2014 (File No. 333-198865), May 7, 2015 (File No. 333-203933), May 4, 2016 (File No. 333-211118), September 1, 2017 (File No. 333-220316) and January 11, 2018 (File No. 333-222516). |
| (3) | This estimate is made pursuant to Rule 457(c) and Rule 457(h)(1) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Ordinary Shares on May 10, 2018, as reported on The Nasdaq Global Select Market. |
| (4) | On September 8, 2015, the Registrant filed a Registration Statement on Form S-4 (File No. 333-206798), as amended (the “S-4 Registration Statement”), and paid a registration fee of $263,533.95. The S-4 Registration Statement was withdrawn by filing a Form RW on December 2, 2015. In accordance with Rule 457(p) under the Securities Act, the Registrant is offsetting the filing fees for this Registration Statement on Form S-8 against the fees previously paid in connection with the S-4 Registration Statement. Accordingly, no additional registration fee is being paid in connection with the filing of this Registration Statement on Form S-8. |
REGISTRATION OF ADDITIONAL SECURITIES
Horizon Pharma Public Limited Company (the “Registrant”) has prepared this Registration Statement on Form S-8 (this “S-8 Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended, to register 10,800,000 additional ordinary shares of the Registrant (the “Ordinary Shares”) issuable under the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan, as amended (the “2014 Plan”), pursuant to an increase in the number of Ordinary Shares reserved for issuance under the 2014 Plan.
INCORPORATION BY REFERENCE OF CONTENTS OF
REGISTRATION STATEMENTS ON FORM S-8
This S-8 Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same benefit plan is effective.
The Registrant’s Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission on September 22, 2014 (File No. 333-198865), May 7, 2015 (File No. 333-203933), May 4, 2016 (File No. 333-211118), September 1, 2017 (File No. 333-220316) and January 11, 2018 (File No. 333-222516) are incorporated by reference in this S-8 Registration Statement pursuant to General Instruction E to Form S-8.
| (1) | Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on May 4, 2017. |
| (2) | Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on May 7, 2018. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Dublin, Ireland, on May 11, 2018.
| HORIZON PHARMA PUBLIC LIMITED COMPANY | ||
| By: | /s/ Timothy P. Walbert | |
| Timothy P. Walbert | ||
| Chairman, President and Chief Executive Officer | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Timothy P. Walbert and Paul W. Hoelscher, and each of them, as his or her true and lawful attorney-in-fact and agent, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature |
Title |
Date | ||
| /s/ Timothy P. Walbert |
Chairman, President and Chief Executive Officer (Principal Executive Officer) |
May 11, 2018 | ||
| Timothy P. Walbert | ||||
| /s/ Paul W. Hoelscher |
Executive Vice President and Chief Financial Officer (Principal Financial Officer) |
May 11, 2018 | ||
| Paul W. Hoelscher | ||||
| /s/ Miles W. McHugh |
Senior Vice President and Chief Accounting Officer (Principal Accounting Officer) |
May 11, 2018 | ||
| Miles W. McHugh | ||||
| /s/ William F. Daniel |
Director | May 11, 2018 | ||
| William F. Daniel | ||||
| /s/ Michael Grey |
Director | May 11, 2018 | ||
| Michael Grey | ||||
| /s/ Jeff Himawan, Ph.D. |
Director | May 11, 2018 | ||
| Jeff Himawan, Ph.D. | ||||
| /s/ Ronald Pauli |
Director | May 11, 2018 | ||
| Ronald Pauli | ||||
| /s/ Gino Santini |
Director | May 11, 2018 | ||
| Gino Santini | ||||
| /s/ James Shannon, M.D. |
Director | May 11, 2018 | ||
| James Shannon, M.D. | ||||
| /s/ H. Thomas Watkins |
Director | May 11, 2018 | ||
| H. Thomas Watkins | ||||
| /s/ Pascale Witz |
Director | May 11, 2018 | ||
| Pascale Witz | ||||